Invasive Candidiasis Clinical Trial
Official title:
Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients
This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit (SICU) patients. Subjects will be stratified by APACHE II score and randomized in 3:1 fashion to either biweekly surveillance using the β-D-glucan assay or standard care. Subjects in the active monitoring arm will receive intravenous anidulafungin should the β-D-glucan exceed 60 pg/mL on a single determination. Subjects in the standard care arm will have biweekly blood draws for β-D-glucan, but the specimens will be batched and tested retrospectively. Antifungal use in the standard care arm is at the discretion of the treating physicians. The primary study end-points are the feasibility of a preemptive antifungal strategy in a SICU setting, β-D-glucan test characteristics, and the safety and tolerability of preemptive anidulafungin. Risks associated with study participation include the risks associated with blood draws, study drug related side effects, and the potential for loss of confidentiality.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05763251 -
Comparison of Uncomplicated Candidemia Therapy Duration in Children
|
N/A | |
Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
Completed |
NCT02491151 -
Variability of Fluconazole Concentration in Critically Ill Patients
|
N/A | |
Completed |
NCT01716988 -
Pharmacokinetics of Micafungin in Critically Ill Patients
|
N/A | |
Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00786903 -
Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?
|
N/A | |
Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 | |
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT03538912 -
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
|
N/A | |
Completed |
NCT02801682 -
NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
|
||
Completed |
NCT02164890 -
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
|
Phase 4 | |
Completed |
NCT02841501 -
Genetic Susceptibility Factors for Candidemia.
|
||
Completed |
NCT01047267 -
Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT02734862 -
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
|
Phase 2 | |
Completed |
NCT01773876 -
Empirical Antifungal Treatment in ICUS
|
Phase 3 | |
Completed |
NCT00689338 -
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
|
Phase 3 | |
Terminated |
NCT03906916 -
Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin
|
Phase 4 |